Difference between revisions of "Mitomycin (Mutamycin)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 1: Line 1:
 
==General information==
 
==General information==
Class/mechanism: Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking.  At higher concentrations, can also inhibit RNA and protein synthesis.<ref name="insert">[http://patient.cancerconsultants.com/druginserts/Mitomycin.pdf Mitomycin (Mutamycin) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/mitomycin.pdf Mitomycin (Mutamycin) package insert (locally hosted backup)]</ref>
+
Class/mechanism: Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking.  At higher concentrations, can also inhibit RNA and protein synthesis.<ref name="insert">[http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-251-01%20MIT%205MG/5539025101 Mitomycin (Mutamycin) package insert]</ref><ref>[[Media:Mitomycin.pdf | Mitomycin (Mutamycin) package insert (locally hosted backup)]]</ref>
 
<br>Route: IV
 
<br>Route: IV
 
<br>Extravasation: [[vesicant]]
 
<br>Extravasation: [[vesicant]]

Revision as of 21:59, 18 March 2017

General information

Class/mechanism: Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. At higher concentrations, can also inhibit RNA and protein synthesis.[1][2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 8/24/1981: Initial FDA approval

Also known as

Mitomycin-C, MTC, Mitozytrex

References